Zentalis Pharmaceuticals
ZNTL
ZNTL
110 hedge funds and large institutions have $1.15B invested in Zentalis Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 40 increasing their positions, 35 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
0.05% more ownership
Funds ownership: 112.74% → 112.79% (+0.05%)
11% less capital invested
Capital invested by funds: $1.29B → $1.15B (-$140M)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Holders
110
Holding in Top 10
3
Calls
$608K
Puts
$471K
Top Buyers
| 1 | +$34.7M | |
| 2 | +$18.4M | |
| 3 | +$17.3M | |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$11.9M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$7.48M |
Top Sellers
| 1 | -$38.2M | |
| 2 | -$10.3M | |
| 3 | -$4.44M | |
| 4 |
State Street
Boston,
Massachusetts
|
-$4.34M |
| 5 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$3.44M |